Skip to Main Navigation Skip to Page Content

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Allyl isothiocyanate: Target Organs and Levels of Evidence for TR-234

Carcinogenesis Bioassay of Allyl Isothiocyanate (CASRN 57-06-7) in F344/N Rats and B6C3F1 Mice (Gavage Study)

Chemical (Study Title) CASRN	Peer Review Date	Route/Exposure Levels	Study Laboratory
Allyl isothiocyanate 57-06-7	06/23/1981	Gavage 0, 12, 25 MG/KG/50 PER GROUP	Southern Research Institute

Levels of Evidence

Male Rats: Positive

Type	Organ/Tissue (Lesion)
Neoplastic Lesions	Urinary Bladder: TRANSITIONAL CELL PAPILLOMA 0/49 2/49 4/49

Female Rats: Equivocal

Type	Organ/Tissue (Lesion)
Neoplastic Lesions	Subcutaneous Tissue: FIBROSARCOMA 0/50 0/50 3/50

Chemical (Study Title) CASRN	Peer Review Date	Route/Exposure Levels	Study Laboratory
Allyl isothiocyanate 57-06-7	06/23/1981	Gavage 0,12,25 MG/KG/50 PER GROUP	Southern Research Institute

Allyl isothiocyanate: Target Organs and Levels of Evidence for TR-234

Carcinogenesis Bioassay of Allyl Isothiocyanate (CASRN 57-06-7) in F344/N Rats and B6C3F1 Mice (Gavage Study)

Levels of Evidence

Male Rats: Positive

Female Rats: Equivocal

Levels of Evidence

Male Mice: Negative

Female Mice: Negative